Int J Pediatr Otorhinolaryngol:过敏性鼻炎中致病性基因和上游调控因子鉴定

2018-11-11 AlexYang MedSci原创

过敏性鼻炎(AR)是老年人中不可逆转失明的主要起因,最近,有研究人员鉴定了AR中的关键基因和上游调控因子。研究人员利用来源于GEO数据库中的AR基因芯片数据进行了整体的分析来筛选AR致病性基因,并利用GO分析和KEGG富集分析对差异化表达基因(DEGs)进行了功能注释和途径分析。研究人员构建了AR特异性转录调控网络来发现关键的和差异化表达的转录因子(TFs),并对DEGs进行了生物信息学验证。研究

过敏性鼻炎(AR)是老年人中不可逆转失明的主要起因,最近,有研究人员鉴定了AR中的关键基因和上游调控因子。

研究人员利用来源于GEO数据库中的AR基因芯片数据进行了整体的分析来筛选AR致病性基因,并利用GO分析和KEGG富集分析对差异化表达基因(DEGs)进行了功能注释和途径分析。研究人员构建了AR特异性转录调控网络来发现关键的和差异化表达的转录因子(TFs),并对DEGs进行了生物信息学验证。研究人员在2个GEO数据库中得到了相关数据,并在AR和正常对照(NC)之间鉴定了793个DEGs(460个上调,33个下调)。在GO分析和KEGG分析之后,研究发现慢性炎症响应和MAPK信号途径在DEGs中显著富集,并检测到了6个表达基因(CLC, CST1, CRTAM, ILK, STAT1和POSTN)。另外,上述6个基因在GEO:GSE51392数据库中具有相同的模式。

最后,研究人员指出,CLC, CST1和STAT13个基因的异常表达可能参与了AR的致病过程。AP-1通过调控CST1和CLC与AR相关。研究人员指出,他们的发现对开发新的生物标记做出了贡献,并阐释了潜在的病理机制,并为AR新治疗靶标打下基础。

原始出处:

Lei Y, Guo P, An J et al. Identification of pathogenic genes and upstream regulators in allergic rhinitis. Int J Pediatr Otorhinolaryngol. Dec 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1727712, encodeId=c56b1e27712c1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 02 02:22:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718843, encodeId=df5b1e1884352, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Apr 14 06:22:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047040, encodeId=bf1a204e04087, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 23 09:22:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638853, encodeId=7a401638853d6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 25 11:22:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352275, encodeId=487b3522e5c6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Nov 11 12:17:01 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352260, encodeId=68f7352260c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:28:27 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2019-06-02 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1727712, encodeId=c56b1e27712c1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 02 02:22:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718843, encodeId=df5b1e1884352, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Apr 14 06:22:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047040, encodeId=bf1a204e04087, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 23 09:22:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638853, encodeId=7a401638853d6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 25 11:22:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352275, encodeId=487b3522e5c6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Nov 11 12:17:01 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352260, encodeId=68f7352260c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:28:27 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2019-04-14 cnxcy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1727712, encodeId=c56b1e27712c1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 02 02:22:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718843, encodeId=df5b1e1884352, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Apr 14 06:22:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047040, encodeId=bf1a204e04087, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 23 09:22:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638853, encodeId=7a401638853d6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 25 11:22:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352275, encodeId=487b3522e5c6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Nov 11 12:17:01 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352260, encodeId=68f7352260c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:28:27 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1727712, encodeId=c56b1e27712c1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 02 02:22:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718843, encodeId=df5b1e1884352, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Apr 14 06:22:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047040, encodeId=bf1a204e04087, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 23 09:22:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638853, encodeId=7a401638853d6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 25 11:22:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352275, encodeId=487b3522e5c6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Nov 11 12:17:01 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352260, encodeId=68f7352260c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:28:27 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1727712, encodeId=c56b1e27712c1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 02 02:22:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718843, encodeId=df5b1e1884352, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Apr 14 06:22:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047040, encodeId=bf1a204e04087, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 23 09:22:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638853, encodeId=7a401638853d6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 25 11:22:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352275, encodeId=487b3522e5c6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Nov 11 12:17:01 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352260, encodeId=68f7352260c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:28:27 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2018-11-11 天地飞扬

    了解一下,谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1727712, encodeId=c56b1e27712c1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 02 02:22:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718843, encodeId=df5b1e1884352, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Apr 14 06:22:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047040, encodeId=bf1a204e04087, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 23 09:22:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638853, encodeId=7a401638853d6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 25 11:22:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352275, encodeId=487b3522e5c6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Nov 11 12:17:01 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352260, encodeId=68f7352260c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:28:27 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2018-11-11 医者仁心5538

    学习了

    0

相关资讯

儿童过敏性鼻炎,应该如何用药?

随着生活环境的变化,过敏性鼻炎(又称变应性鼻炎)已成为儿童的常见病和多发病。据统计,我国儿童过敏性鼻炎的患病率已高达7.83%~29.42%。过敏性鼻炎难以根治,合理用药非常重要。一、过敏鼻炎与普通感冒的简单鉴别1、病因不同:普通感冒是由病毒(其中鼻病毒约占30%~50%)引起的感染性疾病;而过敏性鼻炎是机体接触过敏原后,由IgE介导的非感染性炎性疾病。2、症状不同:普通感冒常有伴咽痛、发热和全身

Immun Inflamm Dis:永久过敏性鼻炎患者中,MP-AzeFlu治疗效果分析

大多数过敏性鼻炎(AR)患者患有中度到重度以及永久性症状。MP-AzeFlu组合鼻内盐酸氮卓斯汀(AZE)和氟替卡松丙酸酯(FP)可以作为一种新的治疗方法来治疗AR。最近,有研究人员在一个前瞻性的和非介入性研究中探索和评估了MP-AzeFlu在减轻AR症状严重度中的效果。研究人员发现,那些使用MP-AzeFlu的患者的VAS评分从开始的73.4mm(SD.20.3)快速降低到了第28天的31.5m

Int Arch Otorhinolaryngol:过敏性鼻炎患者和健康人群之间的1α-25-二羟维生素D3和lgE水平比较

过敏性鼻炎是最常见的的过敏性疾病之一,并且能够引起生活质量的降低。在过去的几十年中,该疾病患者数目的增加的原因归结到了工业化和生活方式变化。维生素D是一种固醇类激素,在人体中具有显著的免疫条款和抗氧化作用。最近,有研究人员调查了1α-25-二羟维生素D3在过敏性患者中的作用,并比较了与健康人群中该物质的水平。研究总共包括了256名参与者。过敏性鼻炎通过过敏性鼻炎和对哮喘的影响(ARIA)指南来进行

Allergy:青少年到成年人群体中,过敏性鼻炎预测因子分析

虽然儿童的遗传性过敏疾病已经了解很短哦,但是从儿童到成年人中,遗传过敏性疾病的持久性相关知识却非常有限。最近,有研究人员在一个非选择性青少年群体中研究了遗传过敏性疾病和I型敏感症的临床特点,并跟踪调查到成年人阶段。研究人员发现,遗传过敏性疾病的流行度高,并且从青少年(31%)到成年人(57%)过程中具有显著的增加,尤其是过敏性鼻炎,发生率增加的幅度为17.5/1000人/年。成年过敏性鼻炎的儿童时

Ann Allergy Asthma Immunol:奥洛帕他定/莫米松组合鼻用喷雾能够改善季节过敏性鼻炎症状

GSP301鼻用喷雾是抗组胺药物盐酸奥洛帕他定和皮质类固醇糠酸莫米他松的固定剂量组合,并倾向性的用于季节过敏性鼻炎(SAR)的治疗。最近,有研究人员在一个豚草花粉环境暴露环境(EEC)下,评估了一日一次(QD)或者一日二次(BID)下的效果和安全性。研究是一个随机的、双盲的和双模拟研究,研究人员将SAR患者(年龄在18-65岁)随机等分到GSP301 BID组、GSP301 QD组、AzeFlu组

盘点:鼻炎研究进展

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】J Agromedicine:美国农场经营者农药的使用、过敏性鼻炎和哮喘情况分析 最近,有研究人员在美国农场经营者中调查了特殊农药的使用与过敏性鼻炎以及哮喘